Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07425821 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
A Phase 1 study, sponsored by International AIDS Vaccine Initiative.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT07425821: Recruiting Phase 1 study, sponsored by International AIDS Vaccine Initiative.
NCT07425821 is a Phase 1 study that is actively recruiting participants, run by International AIDS Vaccine Initiative. The registered enrollment target is 112 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07425821, a Phase 1 study, is actively recruiting participants, sponsored by International AIDS Vaccine Initiative.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
Primary Outcome
Occurrence, onset, duration, and severity of local and systemic solicited adverse events within 14 days following vaccination
Interventions
- OTHER Placebo
- BIOLOGICAL rVSV∆G-MARV-GP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2026-03-27 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
What NCT07425821 shows while recruiting
NCT07425821 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07425821 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07425821 about?
NCT07425821 is a clinical study titled "A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health". A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
What is the current status of trial NCT07425821?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2026-03-27. Estimated completion is 2028-07.
What interventions are being tested in trial NCT07425821?
The interventions under investigation include: Placebo (OTHER), rVSV∆G-MARV-GP (BIOLOGICAL).
Who is sponsoring clinical trial NCT07425821?
This trial is sponsored by International AIDS Vaccine Initiative, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07425821's enrollment target sits among peer trials
112 508th of 2000 higher than 1,489 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI